244 related articles for article (PubMed ID: 28057017)
1. The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma.
Gravina GL; Mancini A; Marampon F; Colapietro A; Delle Monache S; Sferra R; Vitale F; Richardson PJ; Patient L; Burbidge S; Festuccia C
J Hematol Oncol; 2017 Jan; 10(1):5. PubMed ID: 28057017
[TBL] [Abstract][Full Text] [Related]
2. The novel CXCR4 antagonist, PRX177561, reduces tumor cell proliferation and accelerates cancer stem cell differentiation in glioblastoma preclinical models.
Gravina GL; Mancini A; Colapietro A; Vitale F; Vetuschi A; Pompili S; Rossi G; Marampon F; Richardson PJ; Patient L; Patient L; Burbidge S; Festuccia C
Tumour Biol; 2017 Jun; 39(6):1010428317695528. PubMed ID: 28639900
[TBL] [Abstract][Full Text] [Related]
3. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
[TBL] [Abstract][Full Text] [Related]
4. Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.
de Boüard S; Herlin P; Christensen JG; Lemoisson E; Gauduchon P; Raymond E; Guillamo JS
Neuro Oncol; 2007 Oct; 9(4):412-23. PubMed ID: 17622648
[TBL] [Abstract][Full Text] [Related]
5. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Navis AC; Hamans BC; Claes A; Heerschap A; Jeuken JW; Wesseling P; Leenders WP
J Pathol; 2011 Apr; 223(5):626-34. PubMed ID: 21341272
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Joshi AD; Loilome W; Siu IM; Tyler B; Gallia GL; Riggins GJ
PLoS One; 2012; 7(10):e44372. PubMed ID: 23056179
[TBL] [Abstract][Full Text] [Related]
7. Targeting CXCR4 by a selective peptide antagonist modulates tumor microenvironment and microglia reactivity in a human glioblastoma model.
Mercurio L; Ajmone-Cat MA; Cecchetti S; Ricci A; Bozzuto G; Molinari A; Manni I; Pollo B; Scala S; Carpinelli G; Minghetti L
J Exp Clin Cancer Res; 2016 Mar; 35():55. PubMed ID: 27015814
[TBL] [Abstract][Full Text] [Related]
8. MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.
Jalali S; Chung C; Foltz W; Burrell K; Singh S; Hill R; Zadeh G
Neuro Oncol; 2014 Jun; 16(6):868-79. PubMed ID: 24759636
[TBL] [Abstract][Full Text] [Related]
9. Glioblastoma resistance to anti-VEGF therapy is associated with myeloid cell infiltration, stem cell accumulation, and a mesenchymal phenotype.
Piao Y; Liang J; Holmes L; Zurita AJ; Henry V; Heymach JV; de Groot JF
Neuro Oncol; 2012 Nov; 14(11):1379-92. PubMed ID: 22965162
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models.
Cassinelli G; Lanzi C; Tortoreto M; Cominetti D; Petrangolini G; Favini E; Zaffaroni N; Pisano C; Penco S; Vlodavsky I; Zunino F
Biochem Pharmacol; 2013 May; 85(10):1424-32. PubMed ID: 23466421
[TBL] [Abstract][Full Text] [Related]
11. Effects of sunitinib and bevacizumab on VEGF and miRNA levels on corneal neovascularization.
Cakmak H; Gokmen E; Bozkurt G; Kocaturk T; Ergin K
Cutan Ocul Toxicol; 2018 Jun; 37(2):191-195. PubMed ID: 28874077
[TBL] [Abstract][Full Text] [Related]
12. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis.
Kerbel RS; Guerin E; Francia G; Xu P; Lee CR; Ebos JM; Man S
Breast; 2013 Aug; 22 Suppl 2():S57-65. PubMed ID: 24074794
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effect of NK012, a 7-ethyl-10-hydroxycamptothecin-incorporating polymeric micelle, on U87MG orthotopic glioblastoma in mice compared with irinotecan hydrochloride in combination with bevacizumab.
Kuroda J; Kuratsu J; Yasunaga M; Koga Y; Kenmotsu H; Sugino T; Matsumura Y
Clin Cancer Res; 2010 Jan; 16(2):521-9. PubMed ID: 20068081
[TBL] [Abstract][Full Text] [Related]
14. Sunitinib inhibits tumor growth and synergizes with cisplatin in orthotopic models of cisplatin-sensitive and cisplatin-resistant human testicular germ cell tumors.
Castillo-Avila W; Piulats JM; Garcia Del Muro X; Vidal A; Condom E; Casanovas O; Mora J; Germà JR; Capellà G; Villanueva A; Viñals F
Clin Cancer Res; 2009 May; 15(10):3384-95. PubMed ID: 19417025
[TBL] [Abstract][Full Text] [Related]
15. VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.
Pham K; Luo D; Siemann DW; Law BK; Reynolds BA; Hothi P; Foltz G; Harrison JK
Cancer Lett; 2015 Apr; 360(1):60-7. PubMed ID: 25676691
[TBL] [Abstract][Full Text] [Related]
16. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model.
Sonpavde G; Jian W; Liu H; Wu MF; Shen SS; Lerner SP
Urol Oncol; 2009; 27(4):391-9. PubMed ID: 18534874
[TBL] [Abstract][Full Text] [Related]
17. A Randomized, Open-Label Phase 2 Study of the CXCR4 Inhibitor LY2510924 in Combination with Sunitinib Versus Sunitinib Alone in Patients with Metastatic Renal Cell Carcinoma (RCC).
Hainsworth JD; Reeves JA; Mace JR; Crane EJ; Hamid O; Stille JR; Flynt A; Roberson S; Polzer J; Arrowsmith ER
Target Oncol; 2016 Oct; 11(5):643-653. PubMed ID: 27154357
[TBL] [Abstract][Full Text] [Related]
18. HIF-1α activation mediates resistance to anti-angiogenic therapy in neuroblastoma xenografts.
Hartwich J; Orr WS; Ng CY; Spence Y; Morton C; Davidoff AM
J Pediatr Surg; 2013 Jan; 48(1):39-46. PubMed ID: 23331791
[TBL] [Abstract][Full Text] [Related]
19. Direct effect of bevacizumab on glioblastoma cell lines in vitro.
Simon T; Coquerel B; Petit A; Kassim Y; Demange E; Le Cerf D; Perrot V; Vannier JP
Neuromolecular Med; 2014 Dec; 16(4):752-71. PubMed ID: 25113866
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibition of PFKFB3 and VEGF normalizes tumor vasculature, reduces lactate production, and improves chemotherapy in glioblastoma: insights from protein expression profiling and MRI.
Zhang J; Xue W; Xu K; Yi L; Guo Y; Xie T; Tong H; Zhou B; Wang S; Li Q; Liu H; Chen X; Fang J; Zhang W
Theranostics; 2020; 10(16):7245-7259. PubMed ID: 32641990
[No Abstract] [Full Text] [Related]
[Next] [New Search]
